Psyence Biomedical shares surge 10.93% intraday after announcing psilocybin longevity research initiative.

Psyence Biomedical surged 10.93% intraday after announcing a groundbreaking psilocybin longevity research initiative in collaboration with leading South African researchers. As the first publicly listed company to investigate psilocybin’s potential impact on aging biomarkers, the study aims to evaluate its effects on cellular stress, inflammation, mitochondrial function, and longevity pathways. The initiative, led by neuropsychopharmacology expert Dr. Tanya Calvey, could redefine human longevity and aligns with growing global interest in psychedelic therapies and aging science. Preclinical research highlights psilocybin’s potential to extend lifespan and enhance healthspan, positioning Psyence BioMed at the forefront of a high-growth sector. The announcement, emphasizing scientific innovation and market differentiation, likely drove the sharp intraday rally.